[2] [2] FARIA J, NEGALHA G, AZEVEDO A, et al. Metformin and breast cancer: molecular targets[J]. Journal of Mammary Gland Biology and Neoplasia, 2019, 24(2): 111-123.

[4] [4] TSCHERNIA N P, GULLEY J L. Tumor in the crossfire: inhibiting TGF- to enhance cancer immunotherapy[J]. BioDrugs, 2022, 36(2): 153-180.

[5] [5] LIN J. Concern about: echinacoside exerts anti-tumor activity via the miR-503-3p/TGF-1/Smad aixs in liver cancer[J]. Cancer Cell International, 2021, 21(1): 617.

[6] [6] MA R, YI B, RIKER A I, et al. Metformin and cancer immunity[J]. Acta Pharmacologica Sinica, 2020, 41(11): 1403-1409.

[7] [7] NG C W, JIANG A A, TOH E M S, et al. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression[J]. International Journal of Colorectal Disease, 2020, 35(8): 1501-1512.

[8] [8] LU T, LI M, ZHAO M, et al. Metformin inhibits human nonsmall cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway[J]. Cancer Immunol Immunother, 2022, 71(7): 1733-1746.

[9] [9] KANG B G, SHENDE M, INCI G, et al. Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification[J]. Cancer Biology & Therapy, 2023, 24(1): 20-32.

[10] [10] YUAN H, HAN Y, WANG X, et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways[J]. Cancer Cell, 2020, 38(3): 350-365.

[12] [12] MA S, ZHENG Y, XIAO Y, et al. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients[J]. University of Maryland Medicine (Baltimore), 2017, 96(19): e6888.

[13] [13] KIM T S, LEE M, PARK M, et al. Metformin and dichloroacetate suppress proliferation of liver cancer cells by inhibiting mTOR complex 1[J]. International Journal of Molecular Sciences, 2021, 22(18): 10027.

[16] [16] HACHIM M Y, HACHIM I Y, DAI M, et al. Differential expression of TGF isoforms in breast cancer highlights different roles during breast cancer progression[J]. Tumor Biology, 2018, 40(1): 1010428317748254.

[18] [18] WU X, ZHAO J, RUAN Y, et al. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-1-induced EMT and confers paclitaxel resistance in ovarian cancer[J]. Cell Death & Disease, 2018, 9(11): 1102.